Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS -- InvestorBrandNetwork Announces Gamechangers LIVE Interview with FuelPositive Corp. CEO Ian Clifford
LOS ANGELES, Sept. 09, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company focused on manufacturing, licensing, partnership and acquisition opportunities building upon various technological achievements, recently appeared on Gamechangers LIVE, a podcast series putting a spotlight on individuals who are gamechangers in their fields and sharing perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners.
The broadcast, hosted by Executive Coach and Speaker Sergio Tigera, is available for on-demand viewing on Gamechangers LIVE (
NEWS -- Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021.
Heat Biologics' presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021 at 7:00 AM Eastern Time.
The webcast can be accessed here (https://journey.ct.events/view/1a62ca3e-9da6-4fc1-970c-4211c9f86cbc) and on the investor relations section of Heat Biologics' website at https://ir.heatbio.com/. Management will also be participating in one-on-one meetings with qualified members of the investor community throughout the conference.
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
For more information, please visit: https://www.heatbio.com, and also follow us on Twitter.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
NEWS -- FuelPositive Announces Key Appointments to Team
TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) (“FuelPositive” or the “Company”) is delighted to announce the appointment of Nelson Leite as its Chief Operating Officer and a member of the Board of Directors, as well as a number of other key appointments and personnel changes. The Company has been assembling a stellar team of experts to guide it through Phase Two of its growth. No longer solely an R&D company, FuelPositive now has a strong Board, a highly qualified Executive Leadership Team and a growing group of Strategic Advisors to ensure the excellence of its work as it commercializes its lead technology – carbon-free ammonia (NH3).
Nelson brings to FuelPositive over 30 years of experience in various positions as CEO, CTO and VP of Sales and Marketing, including over 20 years as CEO of the robotics and automation company he founded in 1994 and sold in 2014. He began his career as a tool maker through Conestoga College and continued his studies in the mechanical and electrical engineering fields. As a mechatronics specialist, Nelson has led the development of several technologies and inventions including AI software, robotics and machine development, leading to several patents. Nelson has successfully created and executed multiple strategic plans for the path of new technologies from inception to commercialization in the automotive, pharmaceutical and consumer goods industries which are utilized by companies such as Toyota, Tesla and Pfizer, to name a few.
“The team and I are thrilled to have Nelson join us at this pivotal time. He brings decades of experience in the most sophisticated manufacturing processes and disciplines to the Company, right at the time that we are advancing our breakthrough carbon-free NH3 technology. Nelson also cares deeply about the importance of our work related to eliminating carbon emissions,” said FuelPositive CEO and Board Chair Ian Clifford.
Olushola (Shola) Ashiru also joins the FuelPositive Board of Directors as an Independent Director. Based in New York City, Shola is a Partner and Portfolio Manager at New Energy Fund (NEF) II. She has worked in the field of clean technologies since 2007. Shola co-founded New Energy Fund II (a NEF Advisors company), which is a private equity yield fund set up to take equity positions in high yielding renewable energy projects ranging from biofuels, fuel cells, solar and wind, and other fossil fuel replacement technologies, to efficiency and storage options. She started her career in Cleantech Equity Research, then Equity Capital Markets at Ardour Capital Investments. Shola serves as a judge in the annual New York Business Plan Competition, the annual Cleantech Open Northeast competition, and also the annual National Renewable Energy Laboratory’s Industry Growth Forum.
“We are delighted to have Shola join our Board of Directors,” said Ian Clifford. “Her knowledge of the clean technologies sector and capital markets will give us critical insights as we continue to develop our core technology – carbon-free ammonia – and plan our future creating and developing technologies and solutions to fight climate change.”
Francois Desloges has joined FuelPositive’s Executive Leadership Team as Senior Research Scientist. François has over 25 years of experience in high tech entrepreneurship. With a degree in electrical engineering from Polytechnique de Montreal, he has developed core electronic systems, software applications and material science for start-up companies. An out-of-the-box-thinker obsessed with quality, François has always preferred small teams and projects with the potential to disrupt the status quo. In recent years, he has enjoyed contributing to ventures that resonate with his ethical values, whether in the area of privacy or the transition to carbon-free energy sources.
“I have had the pleasure of working with Francois for many years and I know that he brings a level of passion, thoroughness and professionalism to every project he is involved in. Francois is also deeply committed regarding the absolute necessity for profound environmental change. He is a great addition to our like-minded team,” said Clifford.
Jennifer Spencer has also joined the Company’s Executive Leadership Team as Director of Communications. Jennifer is a veteran strategist and leader in cause-related communications with a career spanning 40 years. Initially a journalist, she moved to public relations where she worked in leading international and Canadian agencies. She founded and served as President for nine years of Veritas Communications, which quickly became a Canadian sector leader, providing public and government relations services. She directed communications for Canadian Blood Services through its launch and early years to re-establish the trust of Canadians after the Canadian tainted blood tragedy, and worked in the not-for-profit sector for CNIB (Canadian Institute of the Blind), Heart & Stroke and March of Dimes Canada.
“Jennifer is a consummate communicator and a person who has managed communications for some of the most important and sensitive issues of our time. We are excited to have her join the FuelPositive team as our scope and message grows to an international level. Jennifer thrives on ensuring that complex messages are accessible to everyone, and we have already experienced her special touch on much of our communications and messaging to date,” added Clifford.
Greg Gooch, BEng, MBA, is retiring as President and a Board Member of the Company and will remain involved as a Strategic Advisor. Greg has been involved with FuelPositive since its early days and remains an important supporter and consultant to the Company.
“Greg has contributed heavily to FuelPositive, providing much-valued guidance as we navigated the early days as a Company. We all wish him well in this new phase of his life,” said Clifford.
You can watch an interview about this news release with Ian Clifford, FuelPositive CEO, on our YouTube channel: https://youtu.be/_5yv2DD1tnk
Option Grant
In connection with the appointments of Nelson Leite and Olushola (Shola) Ashiru, the Company has granted them an aggregate of 3,500,000 incentive stock options exercisable at a price of $0.185, until September 8, 2026. The options vest over a period of 18 months, with one-quarter vesting immediately and a further quarter vesting every six months thereafter.
About Fuel Positive
FuelPositive is a Canadian growth-stage technology company committed to providing commercially viable and sustainable “cradle to cradle” clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications. By focusing on technologies that are clean, economically advantageous/ realizable and that leverage existing infrastructure, the Company aims to change the course of climate change through practical solutions that can be implemented now.
The Company’s core technology, carbon-free NH3, takes air, water and sustainable electricity and converts it to a non-polluting chemical for multiple applications, fertilizer for farming, fuel for combustion engines and a solution for grid storage. It is being considered as a replacement for fossil fuels and as the enabler of the hydrogen economy.
FuelPositive is currently building its Phase 2 Hydrogen-Ammonia Synthesizer commercial prototype systems with partner National Compressed Air Canada Ltd. This will confirm the broad application potential for its carbon-free NH3 technology. The modular and transportable systems, which are being built to shipping container configurations, will be adaptable to multiple applications.
Production of the prototype systems is scheduled to be completed by the end of 2021, with demonstration pilot projects being planned for 2022. The Company is initially focusing on the agriculture sector where farmers will be able to produce carbon-free NH3 on their farms and use it to fertilize their fields and fuel their farming equipment, generators, coolers and grain drying equipment.
Cautionary Statement
Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") that are based on expectations, estimates and projections as at the date of this news release. The information in this release about future plans and objectives of the Company are forward-looking statements.
These forward-looking statements are based on assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect.
Many of these uncertainties and contingencies can directly or indirectly affect actual results and could cause actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Forward-looking information is provided for the purpose of providing information about management's expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking information or to explain any material difference between subsequent actual events and such forward-looking information, except to the extent required by applicable law.
For Media or Investor enquiries, please contact:
Ian Clifford
FuelPositive Chief Executive Officer
mailto://investors@fuelpositive.com
https://www.fuelpositive.com
Investor Relations (U.S.):
RBMG - RB Milestone Group LLC
Trevor Brucato, Managing Director
mailto://fuelpositive@rbmilestone.com
NEWS -- CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
MONMOUTH JUNCTION, N.J., Sept. 8, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces a special Company webinar highlighting the topline results of CytoSorbents' U.S. CTC Multicenter Registry that demonstrate high survival using CytoSorb® in Critically Ill COVID-19 patients on ECMO, on Monday, September 13, 2021, at 5:00 p.m. EDT.
CytoSorbents Announces Webinar on Topline Results from U.S. CTC Registry using CytoSorb® in COVID-19 Patients on ECMO
The CTC Registry included 52 consecutive critically ill COVID-19 patients with refractory acute respiratory distress syndrome (ARDS) on life support with ECMO and CytoSorb, enrolled at five U.S. medical centers under FDA Emergency Use Authorization. The prerecorded presentation, geared towards clinicians, will be hosted by Dr. Phillip Chan, CytoSorbents' CEO and feature an overview of CytoSorb and its application in ECMO by Dr. Chan, a review of the CTC Registry results by Dr. J. W. Awori Hayanga, Professor of Cardiovascular and Thoracic Surgery at the West Virginia University School of Medicine and one of the contributing Site Principal Investigators in the registry, followed by a short question and answer session. The webinar will be available for viewing at any time afterwards with registration.
Date: Monday, September 13, 2021
Time: 5:00 p.m. Eastern
Registration Link: https://cyto.news/webinar-CTC-Registry
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in 68 countries around the world as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" seen in common critical illnesses that may result in massive inflammation, organ failure and patient death. These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist. CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. More than 143,000 CytoSorb devices have been delivered to date. CytoSorb was originally introduced into the European Union under CE-Mark as a first-in-kind cytokine adsorber. Additional CE-Mark label expansions were received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both ticagrelor and rivaroxaban during cardiothoracic surgery. The DrugSorb-ATR™ Antithrombotic Removal System, which is based on the same polymer technology as CytoSorb, has also been granted FDA Breakthrough Designation for the removal of ticagrelor, as well as FDA Breakthrough Designation for the removal of the direct oral anticoagulant (DOAC) drugs rivaroxaban and apixaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery.
CytoSorb has been granted U.S. FDA Emergency Use Authorization in the COVID-19 pandemic as an extracorporeal cytokine adsorber for use in adult, critically ill COVID-19 patients with imminent or confirmed respiratory failure. The CytoSorb device has neither been cleared nor approved for the indication to treat patients with COVID-19 infection. The CytoSorb device is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the CytoSorb device under Section 564(b)(l) of the Act, 21 U.S.C § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb-ATR™, ContrastSorb, and others. For more information, please visit the Company's websites at https://www.cytosorbents.com and https://www.cytosorb.com or follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, anticipated future results and performance, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2021, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Investor Relations Contact:
Terri Anne Powers
Vice President, Investor Relations
and Corporate Communications
(732) 482-9984
mailto://tpowers@cytosorbents.com
U.S. Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
mailto://ekim@rubensteinpr.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/cytosorbents-announces-webinar-discussing-topline-results-from-the-us-ctc-registry-using-cytosorb-in-critically-ill-covid-19-patients-on-extracorporeal-membrane-oxygenation-ecmo-301371747.html
SOURCE CytoSorbents Corporation
NEWS -- Drone Guarder, Inc Chairman and CEO Issues Shareholder Letter with Upcoming Action Plan
TORRANCE, CA, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Drone Guarder “the company” (OTC: DRNG TWTR: @DroneGuarder), a dedicated safety and security surveillance company committed to improving business, school and residential security by combining the most technologically advanced unmanned aerial surveillance systems (UAV ‘Drone’), with revolutionary Artificial Intelligence (‘A.I’) technology, issues the following Shareholder Letter direct from Chairman and CEO, Frank I Igwealor.
***
Dear Shareholder,
It’s with great pleasure to share with you today our vision for the upcoming future for Drone Guarder. Over the last few months, we’ve been working tirelessly through the acquisition to provide a smooth and seamless transition. The next few months will be an inundation of product development, marketing, and outreach to form industry partnerships with the most potential to enhance Shareholder Value and Profitability.
Fundamental Mission
Drone Guarder is committed to researching, developing and bringing to market the most advanced Drones (“Unmanned Aerial Vehicles”), and Artificial Intelligence (‘A.I’) technology based products, with an emphasis on business, school and residential security.
Marketplace Potential for State-of-the-Art Drone Technology
We at Drone Guarder understand the rising concerns in our communities regarding the increase in crime in the US over the past few years. According to FBI.gov, in 2019 there were over 1.1 million reported burglaries in the United States with over 3 billion in property losses -- with barely 1 in 10 of those reported cases solved. (1)
Drone Guarder’s commitment to attack this problem head on by addressing deficiencies in property surveillance then developing, creating and manufacturing next generation technology to overhaul outdated systems currently in place.
Our answer is Drone Guarder. Through developing ways to utilize state-of-the-art programs and equipment, we are in the process of developing Drone technology that has the potential to strengthen both individual and business safety and security.
A rapidly expanding growth industry, the estimated Drone Market Value in 2021 is 20.8 Billion, with a revenue forecast in 2028 to skyrocket to 501.4 Billion (2). With a compound annual growth rate (CAGR) of 57.5% from 2021 to 2028, Drone Guarder looks forward to seizing this rapidly expanding marketplace with innovative technology and aggressive marketing campaigns.
Upcoming Action Plan
As we prepare to flourish in the surveillance marketplace, I am very pleased to announce that our company has secured working capital to develop and manufacture Drone Guarder’s technology utilizing cutting-edge Artificial Intelligence to deliver the most groundbreaking solutions in the surveillance and security marketplace.
We’re excited to share Drone Guarder’s Action Plan for the upcoming months:
NEWS -- Plus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will present a Company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13 – 15, 2021.
Investors interested in arranging a meeting with the Company’s management should contact the H.C. Wainwright conference coordinator.
A webcast of the conference presentation will be available on-demand beginning September 13, 2021 at 7:00 a.m. under the ‘Events’ tab of the Investor Relations section of the Plus Therapeutics website at https://www.plustherapeutics.com. A webcast replay will be accessible for 90 days following the event.
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “will,” “believe,” “plan,” “can,” “enable,” “design,” “intend,” “potential,” “expect,” “estimate,” “project,” “prospect,” “target,” “focus,” “anticipate,” “could,” “should,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the design and potential of the Plus Therapeutics portfolio to reformulate, deliver and commercialize multiple novel, proprietary drugs targeting rare cancers and other diseases and to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs; the potential of the Company’s in-licensed portfolio of investigational drugs; the Company’s intent to advance its CNS oncology portfolio through the clinical development process; the ability of RNL to safely, effectively and conveniently deliver a very high dose of radiation directly into the brain tumor; anticipated benefits of strategic collaborations and license agreements, intellectual property, FDA approval process and government regulation; and the Company’s anticipated milestones and events, including with respect to additional sites, enrollment, pivotal trial planning, IND process, and clinical phase plans for RNL, pipeline expansion through additional drug development candidates, and partnership discussions for RNL, DocePLUS and DoxoPLUS; and future development and/or expansion of its product candidates and therapies in its markets. The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the FDA’s accelerated regulatory pathways; the early stage of the Company’s product candidates and therapies, the results of its research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s history of losses; the Company’s need for, and ability to raise, additional cash or obtain other sources of funding in the immediate future; the Company’s ability to: (a) obtain and maintain regulatory approvals, (b) continue as a going concern, (c) remain listed on the Nasdaq Capital Market, (d) to obtain or maintain sufficient levels of reimbursement for its tests, and (d) to repay or refinance some or all of its outstanding indebtedness; the outcome of the Company’s partnering/licensing efforts; market and economic conditions; the impact of the COVID-19 pandemic on the Company and the effectiveness of the efforts it has taken or may take in the future in response thereto; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
Westwicke/ICR
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
Westwicke/ICR
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
NEWS -- FuelPositive Corp. Featured in Syndicated Broadcast Covering Company’s Hiring of NH3 Technology Patent Co-Inventor Dr. Ghassan Chehade to Lead Prototype Manufacturing
LOS ANGELES, Sept. 08, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers FuelPositive’s recent announcement that it has hired engineer Dr. Ghassan Chehade, one of the co-inventors named on the provisional patent of the company’s technology that will produce carbon-free ammonia (NH3), as Lead Project Engineer.
To hear the audio production, visit: https://nnw.fm/frM0k
To read the original press release, visit: https://nnw.fm/PSd7q
“Ghassan will play a significant role, working closely with National Compressed Air Canada Ltd., as we manufacture our Phase 2 commercial prototype demonstration systems for carbon-free NH3 production,” commented Ian Clifford, CEO of FuelPositive. “The manufacturing of demonstration prototypes is a major milestone for us, as we transition from research and development to the commercialization phase of our growth. Having Ghassan involved daily will ensure success, preparing us for the rollout of our demonstration pilot projects in early 2022.”
The company’s carbon-free NH3 technology takes air, water and sustainable electricity and converts it to a non-polluting chemical for multiple applications, fertilizer for farming, fuel for combustion engines and a solution for grid storage. It is being considered as a replacement for fossil fuels and as the enabler of the hydrogen economy. Not only does the production of FuelPositive’s carbon-free NH3 require much less energy than producing hydrogen on its own, but ammonia stores 65% more hydrogen than highly compressed pure hydrogen, making ammonia the most efficient way to safely store and transport hydrogen.
FuelPositive’s modular and transportable systems, leveraging shipping container configurations, will be adaptable to multiple applications. The company is initially focusing on the agriculture sector, where farmers will be able to produce carbon-free NH3 on their farms and use it to fertilize their fields and fuel their farming equipment, generators, coolers and grain drying equipment.
About FuelPositive Corp.
FuelPositive Corp. is a Canadian growth-stage technology company committed to providing commercially viable and sustainable, “cradle to cradle”, clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications. By focusing on technologies that are clean, economically advantageous/realizable and that leverage existing infrastructure, the company aims to change the course of climate change through practical solutions that can be implemented now. For more information, visit the company’s website at https://www.FuelPositive.com
About NetworkNewsAudio
NetworkNewsAudio (“NNA”), one of 50+ brands within the InvestorBrandNetwork (“IBN”), allows you to sit back and listen to market updates, CEO interviews and AudioPressRelease (“APR”) productions. These audio clips provide snapshots of position, opportunity and momentum. NNA can assist by cutting through the overload of information in today's market, while bringing its clients unparalleled visibility, recognition and brand awareness. IBN is where news, content and information converge. IBN is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, IBN has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of 5,000+ key syndication outlets across the nation.
For more information, visit: https://www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications
InvestorBrandNetwork (IBN)
Los Angeles, California
https://www.InvestorBrandNetwork.com
310.299.1717 Office
mailto://Editor@InvestorBrandNetwork.com
I like this tweet ! About four hours ago.
Video River Networks
@NIHKEV
·
4h
We're working hard with our engineering team on an exciting development with our Electric Vehicles, embracing popular technologies and infusing it into one driving experience. Details coming soon. $NIHK $DRNG $GMPW #ElectricVehicles #Drones #AI #NextSteps
I like this tweet ! About four hours ago.
Video River Networks
@NIHKEV
·
4h
We're working hard with our engineering team on an exciting development with our Electric Vehicles, embracing popular technologies and infusing it into one driving experience. Details coming soon. $NIHK $DRNG $GMPW #ElectricVehicles #Drones #AI #NextSteps
NEWS -- FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) Making the Hydrogen Economy Possible Through Its Carbon-Free Ammonia System
We’ve all heard about the hydrogen economy. So why isn’t it happening?
In 2019, the transportation sector generated 29% of the total greenhouse gas emissions in the United States, the highest of the main economic sectors (https://ibn.fm/Jy6VS). According to 2020 statistics from the U.S. Energy Information Administration (“EIA”), gasoline accounted for 56% of the country’s transportation energy use, while diesel was responsible for 24%. In total, petroleum products accounted for a whopping 90% of the energy use (https://ibn.fm/7h2gQ), demonstrating the heavy reliance on these fossil fuels despite the growing availability of electric vehicles and all the talk about the hydrogen economy.
The hydrogen economy envisions a future where carbon-free hydrogen is used for energy storage, long-distance transportation of energy, and as fuel for vehicles and heat generation. With the heightened consciousness around emissions spearheaded by governments setting net-zero greenhouse emission targets, carbon-free “green” hydrogen is emerging as a key piece of the zero-emissions puzzle.
As a fuel, hydrogen has no rival — it burns cleanly and produces more power per unit of weight than gasoline or diesel or even lithium-ion batteries. But moving to the hydrogen economy is not as simple as it sounds. There are practical problems that have so far prevented its implementation. FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a company committed to clean energy solutions, is making the green hydrogen economy possible through its proprietary carbon-free ammonia (“NH3”) system.
While hydrogen is an ideal energy carrier that can help address numerous energy issues, its use faces several hurdles. Firstly, blue and grey hydrogen production (the only kind today) using the traditional methods is energy intensive and almost entirely relies on fossil fuels. According to the International Energy Agency (“IAE”), about 6% of natural gas and 2% of coal produced globally go into hydrogen production. As a result, it is responsible for about 830 million tons of CO2 emissions per year (https://ibn.fm/NurmL). That is not acceptable since the purpose behind the hydrogen economy is to reduce greenhouse gas emissions. Even when sustainable electricity is used to produce green hydrogen, it is an extremely energy intensive process.
Secondly, once produced, hydrogen is extremely volatile. Being lighter than air and even gasoline vapor, hydrogen rapidly rises and disperses upon escaping. This property is compounded by the fact that hydrogen is highly flammable and requires the lowest ignition energy of any fuel (https://ibn.fm/MbHUo), making it a risk for explosions. This, therefore, necessitates an expensive and safe storage in pressurized containers, which unfortunately presents another problem. As a gas, hydrogen must be compressed to extreme pressures to be adequate for transportation use and as a liquid, it boils off at standard temperatures (e.g., a hypothetical car with a full liquid hydrogen tank sitting in your garage on Friday would have an empty tank on Monday due to room-temperature boil-off).
What about distribution? Hydrogen is known to embrittle steel pipes, necessitating more expensive, specially engineered pipelines to prevent hydrogen from escaping. Hydrogen is the smallest element on the periodic table. It’s so small it can even work its way in between the crystalline structure of metals, making them brittle and susceptible to cracking and failure. But hydrogen can be transported in chemical carriers, including liquid inorganic carriers such as ammonia. This is where FuelPositive’s carbon-free NH3 comes in.
NHHHF’s patent-pending first-of-its-kind system enables the company to produce NH3 without relying on hydrocarbons in a dramatically less expensive process. The system also requires 30% less energy than conventional NH3 production methods.
What’s more, carbon-free ammonia, which is made up of about 17.8% hydrogen by weight, also contains a higher volumetric hydrogen density/content than both liquid and compressed hydrogen. FuelPositive puts the figure at 65% more hydrogen than highly compressed hydrogen (https://ibn.fm/Hm4Pc). A 2020 review titled “Ammonia as effective hydrogen storage” observes that the content is 187% higher when liquid ammonia is used (https://ibn.fm/benoS).
With storage and distribution infrastructure already in place, NH3 can be transported in tanker trucks, through pipelines and on ships. At the same time, FuelPositive’s in-situ carbon-free NH3 modular production systems can be installed with the end users, reducing the reliance on these unnecessary forms of ammonia distribution.
“So, think of ammonia as the perfect carrier of hydrogen, and if the end-user requirement is pure hydrogen, then the safest and most practical way to get that hydrogen where it needs to be is through FuelPositive carbon-free ammonia,” the company concludes.
For more information, visit the company’s website at https://www.FuelPositive.com.
NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
https://www.InvestorWire.com
mailto://Editor@InvestorWire.com
NEWS -- Drone Guarder, Inc. Announces ‘Pink Current’ Status on OTC Markets
TORRANCE, CA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Drone Guarder “the company” (OTC: DRNG TWTR: @DroneGuarder), an unmanned aerial vehicle (UAV ‘Drone’) technologically advanced safety and security company, is pleased to announce the company completed its required financial reporting and has officially become ‘Pink Current’.
Drone Guarder is in the planning and design stages of “Unmanned Aerial Vehicle” surveillance systems to provide state-of-the-art security for businesses, school campuses, and private homes.
As the transition to the new management finalizes, the company looks forward to capitalizing on current technological accomplishments into a productive future.
"Today marks the beginning of our new journey, we’re pleased to announce the transition of Drone Guarder, Inc to Pink Current. Our team has laid the foundation for a productive series of developments for the next upcoming year. We’ve thoroughly analyzed various technological advances in Drone security with the most potential for adding Shareholder Value and we look forward to revealing the plans over the next few weeks.” Chairman and CEO Frank Igwealor.
About Drone Guarder, Inc
Drone Guarder, a subsidiary of Video River Networks, Inc. (OTC: NIHK), is a dedicated safety and security surveillance company committed to maximizing personal security through utilizing the most technologically advanced systems in the unmanned aerial surveillance market. Drone Guarder’s products utilize fully integrated sonar mapping programs that work in tandem with stationery sensory technology, delivering the most robust aerial security system network to-date. The system is equipped with state-of-the-art transmission receptors that allow for rapid communication between the Drone and its users. The complete security array can be navigated and controlled through a secure terminal that can be conveniently accessed through the Drone Guarder App, which is currently in development. Drone Guarder is committed to expanding its technology into new sectors in order to capitalize on emerging markets.
About Chairman and CEO Frank Igwealor
With a passion for building businesses by the community for the community, Chairman and CEO Frank Igwealor is committed to the realization of technological and social inventions that benefit society and empower the less-privileged. With a focus on diversity and social-entrepreneurship, CEO Frank devotes his time to developing businesses that empower the less-privileged to become financially self-sufficient, “realizing the humanity of tomorrow begins with the dreams of today.”
Notice Regarding Forward Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Frank I Igwealor, Chairman and CEO,
370 Amapola Ave Suite 200-A,
Torrance,
CA 90501,
email: mailto://franklin@cbdxfund.com,
Twitter https://twitter.com/droneguarder
NEWS -- Drone Guarder, Inc. Announces ‘Pink Current’ Status on OTC Markets
TORRANCE, CA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Drone Guarder “the company” (OTC: DRNG TWTR: @DroneGuarder), an unmanned aerial vehicle (UAV ‘Drone’) technologically advanced safety and security company, is pleased to announce the company completed its required financial reporting and has officially become ‘Pink Current’.
Drone Guarder is in the planning and design stages of “Unmanned Aerial Vehicle” surveillance systems to provide state-of-the-art security for businesses, school campuses, and private homes.
As the transition to the new management finalizes, the company looks forward to capitalizing on current technological accomplishments into a productive future.
"Today marks the beginning of our new journey, we’re pleased to announce the transition of Drone Guarder, Inc to Pink Current. Our team has laid the foundation for a productive series of developments for the next upcoming year. We’ve thoroughly analyzed various technological advances in Drone security with the most potential for adding Shareholder Value and we look forward to revealing the plans over the next few weeks.” Chairman and CEO Frank Igwealor.
About Drone Guarder, Inc
Drone Guarder, a subsidiary of Video River Networks, Inc. (OTC: NIHK), is a dedicated safety and security surveillance company committed to maximizing personal security through utilizing the most technologically advanced systems in the unmanned aerial surveillance market. Drone Guarder’s products utilize fully integrated sonar mapping programs that work in tandem with stationery sensory technology, delivering the most robust aerial security system network to-date. The system is equipped with state-of-the-art transmission receptors that allow for rapid communication between the Drone and its users. The complete security array can be navigated and controlled through a secure terminal that can be conveniently accessed through the Drone Guarder App, which is currently in development. Drone Guarder is committed to expanding its technology into new sectors in order to capitalize on emerging markets.
About Chairman and CEO Frank Igwealor
With a passion for building businesses by the community for the community, Chairman and CEO Frank Igwealor is committed to the realization of technological and social inventions that benefit society and empower the less-privileged. With a focus on diversity and social-entrepreneurship, CEO Frank devotes his time to developing businesses that empower the less-privileged to become financially self-sufficient, “realizing the humanity of tomorrow begins with the dreams of today.”
Notice Regarding Forward Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Frank I Igwealor, Chairman and CEO,
370 Amapola Ave Suite 200-A,
Torrance,
CA 90501,
email: mailto://franklin@cbdxfund.com,
Twitter https://twitter.com/droneguarder
Elon Musk got in trouble with his tweets , let's hope Vivos learns from that.
NEWS -- Video River Networks has retained Law Office of Heskett & Heskett for assistance with Name and Ticker Symbol Change
TORRANCE, CA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Video River Networks “the company” (OTC: NIHK TWTR: @NIHKEV), an Electric Vehicles, Battery, Robotics, Drones and Machine Learning Technology holding company, is pleased to announce it has retained the Law Office of Heskett & Heskett for assistance with its NAME and TICKER SYMBOL process with Finra (“Financial Industry Regulatory Authority”).
"I’m excited to announce we’ve chosen a new name for Video River Networks, Inc. that reflects our development and commitment as a growth driven technology company. I’m looking forward to sharing it once we’ve gotten approval from Finra, and I’m grateful Heskett & Heskett has joined to assist us in that objective.” CEO Frank Igwealor.
About Video River Networks, Inc.
Video River Networks, Inc. is an Electric Vehicles and Battery Technology company whose focus is to develop and bring to market the next generation of high-performance state-of-the-art Electric Vehicles. The company’s current and expanding technology portfolio includes Electric Vehicles, Artificial Intelligence, Machine Learning and Robotic ("EV-AI-ML-R") assets, with businesses and operations in North America and Asia. With a commitment to revolutionary technology, Video River Networks is in the process of cultivating innovative technologies to enhance consumer’s technology experience.
For more information, please check the latest updates on the company's Twitter account https://twitter.com/NIHKEV
Notice Regarding Forward Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
CONTACT:
Video River Networks, Inc.
370 Amapola Ave., Suite 200A
Torrance, CA 90501
mailto://contact@videorivernetworks.net
North America also includes Canada .
NEWS -- Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug
RadioMedix, Inc. is a key manufacturer and supplier of cGMP radiotherapeutics for late-stage clinical trials and commercial production
RadioMedix will produce cGMP drug product for Rhenium-186 NanoLiposome (186RNL) and may extend to future products under the RNL platform
AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it has entered into an agreement with RadioMedix, Inc. (RadioMedix) for the commercial production of the Company’s radiopharmaceuticals.
“RadioMedix is a global leader in the development and production of GMP radiopharmaceutical products,” said Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. “This strategic partnership substantially supports our efforts to have fully compliant 186RNL available by mid-2022 for a potential Phase 2/3 clinical study in adults with recurrent glioblastoma (GBM).”
“We are very excited to be the GMP manufacturing arm of Plus Therapeutics and participate in the development of 186RNL, a promising radiotherapeutic for central nervous system tumors. Our investment in state-of-the-art facilities for radiopharmaceutical manufacturing and highly trained experts emphasizes our commitment to delivering positive customer experiences across all phases of radiopharmaceutical development and commercial manufacturing,” said Ebrahim S. Delpassand, M.D., Chairman and Chief Executive Officer of RadioMedix.
Under the agreement, RadioMedix will produce cGMP drug product meeting all applicable requirements of the U.S. Food and Drug Administration (FDA) and similar global regulatory entities. This strategic partnership further secures the commercial supply chain for 186RNL and extends to future products under the RNL platform.
186RNL is being developed to treat recurrent GBM, leptomeningeal metastases, and pediatric brain cancer. It has been designed to safely, effectively and conveniently deliver high doses of radiation to rare and central nervous system tumors. Plus Therapeutics is currently enrolling patients with recurrent GBM in the U.S. NIH-supported multi-center ReSPECT™-GBM Phase 1 dose-finding clinical trial.
About Plus Therapeutics, Inc.
Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative, targeted radiotherapeutics with nanoliposome-encapsulated radionuclides for rare and difficult-to-treat cancers. Central to the Company’s drug development is a unique nanotechnology platform designed to formulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
About RadioMedix, Inc
RadioMedix is a Houston, Texas-based biotechnology company with 21 CFR 211 compliant cGMP manufacturing and analytical suites for human clinical trials, and commercial phase manufacturing for radiopharmaceuticals. For more information, please visit http://radiomedix.com/
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “will,” “believe,” “plan,” “can,” “enable,” “design,” “intend,” “potential,” “expect,” “estimate,” “project,” “prospect,” “target,” “focus,” “anticipate,” “could,” “should,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the Company’s anticipated expenditures, including research and development, sales and marketing, and general and administrative expenses; anticipated benefits of strategic collaborations and license agreements, intellectual property, FDA approval process and government regulation; the Company’s ability to benefit from the NIH/NCI award for continued clinical development of 186RNL for recurrent glioblastoma; the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; the Company’s ability to expand clinical testing of 186RNL to additional sites; the potential size of the market for the Company’s product candidates; the Company’s research and development efforts; the Company’s IP strategy; competition; future development and/or expansion of its product candidates and therapies in its markets; the Company’s ability to generate product or development revenue and the sources of such revenue; the amounts that the Company may be obligated to pay under license agreements; the Company’s ability to effectively manage its gross profit margins; its ability to obtain and maintain regulatory approvals; expectations as to the Company’s future performance; the Company’s need for additional financing and the availability thereof; its ability to fully access its equity line with Lincoln Park; any changes to its interest expenses; the Company’s ability to continue as a going concern; its ability to remain listed on the Nasdaq Capital Market; the Company’s ability to repay or refinance some or all of its outstanding indebtedness and its ability to raise capital in the future; expectations as to the impact of recently issued or adopted accounting standards; the Company’s expectations as to the impact of the COVID-19 pandemic on its business and operating results; the Company’s beliefs as to the impact of any liability that may arise as a result of any legal proceedings; and the potential enhancement of the Company’s cash position through development, marketing, and licensing arrangements.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
Westwicke/ICR
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
Westwicke/ICR
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
If I was going to guess who would buy the shares and why the good Doctor let them have a deal on the shares, is the group that helps Vivos at the mayo clinic , think about it , it makes sense .
GS owns a ton of shares he said in one of his tweets.
It is obvious that the company that is doing the offering of 5 million dollars worth of stock knows that this is ready to rock .
NEWS -- Topline Results from CytoSorbents' U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
90-day ICU Mortality was 27% with ECMO + CytoSorb in CTC Registry Data Presented on Day 1 of the International Symposium on Intensive Care and Emergency Medicine. For context, the Extracorporeal Life Support Organization COVID-19 ECMO Registry Reports 50% 90-day Mortality in North America with Standard ECMO Alone
MONMOUTH JUNCTION, N.J., Sept. 1, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification, announced that topline results from its CytoSorb Therapy in COVID-19 (CTC) multicenter registry were presented at the 40th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2021) in Brussels, Belgium yesterday. The CTC Registry included 52 consecutive critically ill COVID-19 patients with refractory acute respiratory distress syndrome (ARDS) on life support with ECMO and CytoSorb enrolled at 5 U.S. medical centers under FDA Emergency Use Authorization (EUA). The primary outcome of 90-day ICU mortality was 27% in the CTC Registry. For context, the 90-day mortality in the North American cohort of the international Extracorporeal Life Support Organization (ELSO) COVID-19 ECMO Registry that includes more than 4,600 adult patients was 50%1. Importantly, all 5 centers participating in the CTC registry reported that CytoSorb was easily integrated in the ECMO circuit and well-tolerated, with no unanticipated device-related adverse events.
Topline Results from U.S. CTC Registry Show High Survival using CytoSorb® in Critically Ill COVID-19 Patients on ECMO
CytoSorb received FDA Emergency Use Authorization in April 2020 for use in critically ill COVID-19 patients, 18 years of age or older with confirmed or imminent respiratory failure to reduce pro-inflammatory cytokine levels, and can be used with a wide range of blood pumps, including ECMO. ECMO is a machine that pumps and oxygenates blood outside of the body, reducing the dependence on the lungs for gas exchange, and allowing mechanical ventilator settings to be lowered to prevent ventilator-induced lung injury. The CTC Registry inclusion criteria required that CytoSorb use adhere strictly to the patient selection criteria and device use guidelines outlined by the EUA, including standardized training and treatment schedules with CytoSorb, thereby providing high fidelity evidence in a relatively uniform study population. Highlights from the presentation included:
NEWS -- Lineage Announces Appointment of General Counsel
CARLSBAD, Calif., September 01, 2021--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has appointed George A. Samuel III as Lineage’s General Counsel and Corporate Secretary. Mr. Samuel will lead the Company’s legal operations, bringing extensive corporate, transactional, intellectual property and commercial expertise which spans nearly 15 years across the life sciences and technology sectors as well as in private practice.
"We are pleased to welcome George to our leadership team and look forward to his contributions as we build Lineage into a leading cell therapy and cell transplant company," stated Brian M. Culley, Lineage CEO. "George’s diverse experience across legal and other operational areas will be invaluable as we continue to execute on our clinical development plans. In particular, his transactional successes in business development and his intellectual property experience will be key resources as we evaluate partnership opportunities and expand collaborations for our OpRegen, OPC1 and VAC2 programs and work to unlock additional value from our extensive intellectual property portfolio."
"I am looking forward to joining this dynamic and experienced team by leading Lineage’s legal operations at this exciting and transformative time," stated George A. Samuel III. "The field of cell therapy is undergoing rapid growth and I’m delighted to have this opportunity to contribute to it."
Prior to joining Lineage, Mr. Samuel most recently served as Director, Senior Counsel for Lytx, Inc., where he managed the commercial legal operations for an international video telematics SaaS company. Prior to that, Mr. Samuel served as VP, General Counsel and Corporate Secretary for Cardiff Oncology, Inc. (formerly known as Trovagene, Inc.), a clinical-stage biotechnology company focused on developing treatments in oncology. While at Cardiff Oncology, he advised on strategic, business development and operational decisions; oversaw capital raising efforts, regulatory compliance as well as SEC reporting; and managed intellectual property, including technology transfer and licensing. Mr. Samuel has also practiced corporate law at major law firms, including DLA Piper LLP and Cooley LLP, where he served as outside counsel to public and private companies in a variety of commercial transactions. Mr. Samuel received a J.D. from Columbia University School of Law, and a B.A. in Philosophy from Tufts University and is a member of the State Bar of California and New York.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s three allogeneic ("off-the-shelf") clinical programs are in markets with billion dollar opportunities: (i) OpRegen®, an investigational retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an investigational oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, with investigational immunotherapy VAC2 currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit https://www.lineagecell.com or follow the Company on Twitter @LineageCell.
Forward-Looking Statements
Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," project," "target," "tend to," "look forward to" or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Lineage’s ability to become a leading cell therapy and cell transplant company, to expand collaborations for its product candidate programs, and to unlock value from its intellectual property portfolio, and the commercial potential for cell therapy products. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks discussed in Lineage’s filings with the Securities and Exchange Commission (the SEC). Further information regarding these risks, uncertainties and factors is included under the heading "Risk Factors" in Lineage’s periodic and other reports filed with the SEC, including Lineage’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available from the SEC’s website. Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005330/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
Solebury Trout IR
Gitanjali Jain Ogawa
(mailto://Gogawa@soleburytrout.com)
(646) 378-2949
Russo Partners – Media Relations
Nic Johnson or David Schull
mailto://Nic.johnson@russopartnersllc.com
mailto://David.schull@russopartnersllc.com
(212) 845-4242
NEWS -- FuelPositive Corp. Featured in Syndicated Broadcast Covering Study Highlighting Breadth of Canadian Green Energy Production Capacity
LOS ANGELES, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers FuelPositive’s recent announcement that it commissioned emissions reduction and carbon credit specialist Andre Mech to conduct an analysis of Canada’s green off-peak electricity capacity and to determine the fuel needs and the carbon emissions of the Canadian transportation sector.
To hear the audio production, visit: https://nnw.fm/gYASe
To read the original press release, visit: https://nnw.fm/Yvz2e
“Switching from fossil fuels to carbon-free ammonia offers a viable, economical transition strategy for Canada’s transportation sector as we adopt new practices to address climate change,” commented Ian Clifford, CEO of FuelPositive. “Many people don’t know it, but planes, trains, ships, trucks and other vehicles can be converted to run on ammonia – just as easily as they can be converted from gasoline and diesel to run on propane. The transportation sector just didn’t see a benefit to switching to ammonia until now, because the production of traditional ammonia results in massive carbon emissions. But, when you use our carbon-free NH3 made from green electricity rather than traditional ammonia, it means we can move people around and transport goods with no pollution.”
The findings of Mech’s analysis were startling. Canada has enough off-peak green electricity today to provide non-polluting, carbon-free NH3 fuel to power 63% of all the passenger cars, light trucks, passenger aviation, buses, light rail, motorcycles, freight trucking, freight aviation, rail, marine and other sector vehicles in the country. But even more exciting, Canada has enough off-peak green electricity to provide carbon-free NH3 to power 100% of the needs of passenger and freight aviation and rail, passenger bus, freight trucking, freight rail and freight marine shipping in Canada – all regulated industries that are notoriously high greenhouse gas emitters with significant government mandates to decarbonize.
“The analysis outlines the opportunities and needs at the provincial and territorial levels,” said study author Andre Mech. Three provinces – Manitoba, Quebec and Newfoundland & Labrador – already generate enough renewable electricity to cover their passenger aviation, passenger rail and freight transportation fuel requirements using FuelPositive’s carbon-free NH3 system. In a national strategy, they would be green ammonia suppliers. The remaining provinces and territories would be green ammonia consumers. According to Mech: “The good news is that there are suppliers and consumers. That tells us that there is a market for green ammonia within Canada itself.”
About FuelPositive Corp.
FuelPositive Corp. is a Canadian growth-stage technology company committed to providing commercially viable and sustainable, “cradle to cradle”, clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications. By focusing on technologies that are clean, economically advantageous/realizable and that leverage existing infrastructure, the company aims to change the course of climate change through practical solutions that can be implemented now. For more information, visit the company’s website at https://www.FuelPositive.com
About NetworkNewsAudio
NetworkNewsAudio (“NNA”), one of 50+ brands within the InvestorBrandNetwork (“IBN”), allows you to sit back and listen to market updates, CEO interviews and AudioPressRelease (“APR”) productions. These audio clips provide snapshots of position, opportunity and momentum. NNA can assist by cutting through the overload of information in today's market, while bringing its clients unparalleled visibility, recognition and brand awareness. IBN is where news, content and information converge. IBN is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, IBN has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of 5,000+ key syndication outlets across the nation.
For more information, visit: https://www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications
InvestorBrandNetwork (IBN)
Los Angeles, California
https://www.InvestorBrandNetwork.com
310.299.1717 Office
mailto://Editor@InvestorBrandNetwork.com
George should not throw stones when he lives in a pumping glass house , his house of cards, his own companies FORW and TSNP ,It would be very easy to put the light on his own dealings and show what a hypocrite he is . Showing what a company can do and being very excited of the future for your company is not a sin , if it is, George carries the same sin .
NEWS -- CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress
MONMOUTH JUNCTION, N.J. and BOLOGNA, Italy, Aug. 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood purification, announce the commercial launch of Aferetica's PerLife™ ex vivo organ perfusion system for kidney and liver transplant and CytoSorbents' PerSorb™ adsorber, based on the CytoSorbents ECOS-300CY™ sorbent technology to remove inflammatory mediators during ex vivo organ perfusion, at the European Society of Organ Transplantation (ESOT) Congress in Milan, Italy from August 29 – September 1, 2021.
CytoSorbents and Aferetica Announce the Commercial Launch of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System
The PerLife and PerSorb technologies will be showcased in Aferetica's Booth #26 in the main exhibit hall and highlighted at the company-sponsored symposium "From Organ Preservation to Organ Regeneration" on Tuesday, August 31, 2021 from 1:15-2:15PM CEST in Turquoise Room 1.
Chairs:
NEWS -- Heat Biologics to Provide Corporate Update
Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced CEO Jeff Wolf will host a conference call on Thursday, September 2nd at 11:00 A.M. Eastern Time to provide an update on the Company’s activities.
The conference call may be accessed by dialing 844-602-0380 for U.S. callers or +1 862-298-0970 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2768/42602 or on the Company’s website at https://ir.heatbio.com/.
An audio replay of the call will be available through September 16, 2021, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and by entering the access code: 42602.
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
For more information, please visit: https://www.heatbio.com, and also follow us on Twitter.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) Hydrogen-Ammonia Technology Drives Advances in Carbon-free Movement
These Are The Cheapest Electric Cars You Can Buy Today
2021 Kia Niro EV EX: $39,090. ...
2021 Nissan Leaf Plus: $38,270. ...
2022 Hyundai Kona Electric: $37,390. ...
2021 Hyundai IONIQ EV: $33,245. ...
2022 Chevrolet Bolt EUV: $33,000. ...
2021 Nissan Leaf: $31,670. ...
2022 Chevrolet Bolt EV: $31,000. ...
2022 Mini Cooper SE: $29,900
Video rivers most expensive electric car is comparable but is also faster and very good looking.
The prices are adjusted for shipping charges , the price we saw before was the price before shipping. But still, the electric car sector is hot and people are waiting months to get one , these will sell .
That news of Lowering the AS is even more important than the Website being up and running Good find !
I think more work will be added to the website which will include pictures of the interior and colors you can order, and accessories and detailed pictures of the car so a buyer can see what it looks like in and out , just the beginning but looking good !
NEWS -- Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary
Developing a new era of precision medicines using a unique and proprietary drug discovery platform
DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the launch of its wholly-owned subsidiary, Skunkworx Bio, Inc. (“Skunkworx”), focused on the development of a drug discovery paradigm to enable rapid drug development.
Skunkworx’s unique, highly diverse, proprietary libraries of “Pocket Biologics” are used to identify miniature proteins which bind to critical domains of druggable targets. The Skunkworx approach aims to enable rapid drug discovery and validation of new innovative therapeutics utilizing advanced computational methods and bioinformatics to further enhance target precision. Skunkworx has successfully identified agonists and antagonists for a number of targets and is in the process of progressing several of these assets through preclinical studies.
Matt Seavey, Ph.D., Skunkworx’s Executive Director of Scientific Operations, commented, “Our unique process flips the paradigm of drug discovery, as it enables us to rapidly identify novel drug targets to determine if a target is druggable. By utilizing this approach, we have been able to identify lead targets and already have several promising programs underway.”
Jeff Wolf, Chief Executive Officer of Heat, commented, “We are extremely proud to launch Skunkworx, an innovative platform to accelerate the path from discovery to preclinical development. Skunkworx augments Heat’s emerging drug development ecosystem designed to efficiently move new biologic programs from discovery into the clinic. New programs will be discovered through Skunkworx, developed at Heat and manufactured at Scorpion Biological Services, Heat’s wholly owned manufacturing subsidiary. This integrated platform is focused on driving innovation by rapidly accelerating the drug development process. We look forward to working with Skunkworx to advance a wide repertoire of drugs across a wide variety of indications, including biosecurity applications, an area of growing importance.”
About Skunkworx Bio.
Skunkworx Bio is developing a new era of precision medicines where “Biology drives Innovation.” The Company’s “Pocket Biologics” are therapeutics derived from its antibody and small protein libraries. Skunkworx has integrated computational and bioinformatic analysis to its biology-based drug discovery paradigm. The goal is to “accelerate” the time from discovery to moving its drug leads into formal preclinical development. For more information, please visit: https://www.skunkworx.bio.
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
For more information, please visit: https://www.heatbio.com, and also follow us on Twitter.
Forward Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements regarding Skunkworx’s approach aiming to enable rapid drug development and validation of new precision therapeutics, utilizing advanced computational methods and bioinformatics to further enhance their target precision, Skunkworx, as a potentially revolutionary drug discovery company, the Skunkworx platform accelerating the path from discovery to preclinical, Skunkworx enabling Heat to efficiently move new biologic programs from discovery into the clinic and advancing a wide repertoire of drugs across the spectrum of oncology, inflammation, infectious diseases, and other indications, including biosecurity applications, an area of growing importance.. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Skunkworx to enable rapid drug development and accelerate the path from discovery to preclinical and to enable Heat to efficiently move new biologic programs from discovery into the clinic and advancing a wide repertoire of drugs across the spectrum of oncology, inflammation, infectious diseases, and other indications, including biosecurity applications, an area of growing importance, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities and its cash and short-term investments providing significant runway to fund Heat’s current clinical programs and further expand Heat’s therapeutic portfolio , its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's annual report on Form 10-K for the year ended December 31, 2020 filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
I own NIHK and DRNG I am thinking of buying some GMPW does anyone know the current shares outstanding and the float.
$NIHK is still on track to timely file its June 30, 2021 10-Q within the 10 extra days afforded the Company by the NT 10-Q.
— Tytan Cybernetics (@NIHKEV) August 24, 2021
He is far from a moron, if he controls several companies, he looks very smart to me, I think George was jealous that our CEO is smarter than he is, and wanted to control him , George acts like he is an absolute saint, yet he constantly pumps stocks .
CEO’s Statement of Commitment to Values in the OTC
TORRANCE, CA, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Video River Networks, Inc. (OTC PINK:NIHK) (the "Company")
Dear NIHK, GMPW, DRNG Shareholders and the Communities We Serve,
I'm writing this letter in response to some completely biased, liable and unfair attacks on Twitter against both me and my wife generated by George Sharp @GeorgeASharp.
It's unfortunate I need to take time out to address these ridiculous allegations, but out of respect for my Shareholders and the communities we serve, I feel these attacks necessitate a swift and definitive response.
As many of you are already familiar, the OTC 'Over the Counter’ stock exchange is filled with companies that begin as a dream; as a vision to try and find a way to make the world around us a better place. Many OTC companies fail over time, but with hard work and perseverance a handful emerge victorious, up-listing the OTC exchanges and eventually landing the dream of all OTC stocks: a listing on a more prestigious exchange.
The pathway from OTC dream to a more prestigious exchange is fueled by the passion of the community, both the early employees of these fledgling companies and the early stockholders who seize hold of the dream and share in the vigilance to bring that dream to life.
As a CEO, I take great pride in listening to the needs of everyone involved in bringing these fledging dreams to reality: I communicate and listen to my employees, my clients, my customers and of course from my Shareholders as well.
As equity holders in my companies, my Shareholders have placed their hard earned money -- sometimes their only few extra dollars they have left -- into my companies and they deserve my attention and respect.
Whether a Shareholder has one Twitter follower or a million Twitter followers, it is completely irrelevant and I treat all of my Shareholders with the same attention and respect. I encourage all of my Shareholders to bring ideas for each of my companies.
As a CEO of OTC companies, our initial financial resources are notoriously limited, making the minds and suggestions of my Shareholders one of our greatest assets to building pathways to future success.
When I sign my name CEO Frank, I make a commitment to learn from the challenges in front of me in order to do everything I can to bring both passion and value to the companies I serve.
I will always stand by my commitment to listen to the OTC community: my employees, my clients, and of course my valued Shareholders.
Together, we can achieve great success. Yours sincerely,
CEO Frank
About Video River Networks, Inc.
Video River Networks, Inc. is an Electric Vehicles and Battery Technology holding company that operates and manages a portfolio of Electric Vehicles, Artificial Intelligence, Machine Learning and Robotics ("EV-AI-ML-R") assets, businesses and operations in North America. The Company's current and target portfolio businesses and assets include operations that design, develop, manufacture and sell high-performance fully electric vehicles and design, manufacture, install and sell Power Controls, Battery Technology, Wireless Technology, and Residential utility meters and remote, mission-critical devices mostly engineered through Artificial Intelligence, Machine Learning and Robotic technologies. NIHK's current technology-focused business model is a result of our board resolution on September 15, 2020 to spin-in/off our specialty real estate holding business to an operating subsidiary and then pivot back to being a technology company. The Company has now returned back to its original technology-focused businesses of Power Controls, Battery Technology, Wireless Technology, and Residential utility meters and remote, mission-critical devices. For more information and the latest updates check the company's Twitter account at https://twitter.com/NIHKEV
CONTACT:
Video River Networks, Inc.
370 Amapola Ave., Suite 200A
Torrance, CA 90501
contact@videorivernetworks.net
https://www.globenewswire.com/news-release/2021/08/24/2285159/0/en/CEO-s-Statement-of-Commitment-to-Values-in-the-OTC.html
NIHK $$$
Classic BS Basher article so shorts can recover shares on all Franks works.